The ORR for all patients was 9.9%, more specifically, patients with adenocarcinoma showed a 5.2% ORR; subgroup analysis showed that ORR was 2-fold higher in PD-L1 positive tumors (PD-L1 CPS of 10 or higher) (13.8%) compared to PD-L1 negative tumors (6.3%). This evidence concerns the gene CD274 and adenocarcinoma.